

From: [Megan Raymond](#)
To: [Trials](#); [Molenda, John](#); [Underwood, Cathy](#); white-ptab@perkinscoie.com; greb-ptab@perkinscoie.com; prochnow-ptab@perkinscoie.com; jones-ptab@perkinscoie.com; tietz-ptab@perkinscoie.com; lembo-ptab@perkinscoie.com; [J. Steven Baughman](#); [Green, Michael](#); [Doh, Tyler](#); [Kass, Lawrence](#); [Michael Milea](#); [Joshua Reich](#); [MtrDist]
[Semaglutide](#)
Subject: IPR2024-00631
Date: Monday, March 11, 2024 11:11:14 AM

CAUTION: This email has originated from a source outside of USPTO. PLEASE CONSIDER THE SOURCE before responding, clicking on links, or opening attachments.

Petitioner filed Paper 4 and Exhibit 1507 under seal in the above-reference matter, with “Availability” through P-TACTS set for only the Filing Party and Board. Under 37 CFR 42.55, Patent Owner hereby consents to the default protective order and requests access to the paper and exhibit through P-TACTS.

Sincerely,
Megan Raymond
Counsel for Patent Owner

From: Trials <Trials@USPTO.GOV>
Sent: Monday, March 11, 2024 10:33 AM
To: Megan Raymond <megan.raymond@groombridgewu.com>; Molenda, John <jmolenda@steptoe.com>; Underwood, Cathy <Cathy.Underwood@USPTO.GOV>; white-ptab@perkinscoie.com; greb-ptab@perkinscoie.com; prochnow-ptab@perkinscoie.com; jones-ptab@perkinscoie.com; tietz-ptab@perkinscoie.com; lembo-ptab@perkinscoie.com; J. Steven Baughman <steve.baughman@groombridgewu.com>; Green, Michael <migreen@steptoe.com>; Doh, Tyler <tdoh@steptoe.com>; Kass, Lawrence <lkass@steptoe.com>; Michael Milea <mike.milea@groombridgewu.com>; Joshua Reich <joshua.reich@groombridgewu.com>; [MtrDist] Semaglutide <Semaglutide@Steptoe.com>
Cc: Trials <Trials@USPTO.GOV>
Subject: RE: Conference Call - IPR2023-00724 and IPR2024-00631

Counsel,

The conference call dial-in number is: [REDACTED] and the passcode is: [REDACTED].

Regards,

Esther Goldschlager
Supervisory Paralegal Specialist
Patent Trial & Appeal Board
U.S. Patent & Trademark Office

From: Megan Raymond <megan.raymond@groombridgewu.com>

Sent: Monday, March 11, 2024 10:29 AM

To: Molenda, John <jmolenda@steptoe.com>; Underwood, Cathy <Cathy.Underwood@USPTO.GOV>; white-ptab@perkinscoie.com; greb-ptab@perkinscoie.com; prochnow-ptab@perkinscoie.com; jones-ptab@perkinscoie.com; tietz-ptab@perkinscoie.com; lembo-ptab@perkinscoie.com; J. Steven Baughman <steve.baughman@groombridgewu.com>; Green, Michael <migreen@steptoe.com>; Doh, Tyler <tdoh@steptoe.com>; Kass, Lawrence <lkass@steptoe.com>; Michael Milea <mike.milea@groombridgewu.com>; Joshua Reich <joshua.reich@groombridgewu.com>; [MtrDist] Semaglutide <Semaglutide@Steptoe.com>
Cc: Trials <Trials@USPTO.GOV>
Subject: RE: Conference Call - IPR2023-00724 and IPR2024-00631

CAUTION: This email has originated from a source outside of USPTO. **PLEASE CONSIDER THE SOURCE** before responding, clicking on links, or opening attachments.

Hello,

The passcode for this call does not seem to be valid.

Sincerely,
Megan Raymond

From: Megan Raymond <megan.raymond@groombridgewu.com>
Sent: Friday, March 8, 2024 10:46 AM
To: Molenda, John <jmolenda@steptoe.com>; Underwood, Cathy <Cathy.Underwood@USPTO.GOV>; white-ptab@perkinscoie.com; greb-ptab@perkinscoie.com; prochnow-ptab@perkinscoie.com; jones-ptab@perkinscoie.com; tietz-ptab@perkinscoie.com; lembo-ptab@perkinscoie.com; J. Steven Baughman <steve.baughman@groombridgewu.com>; Green, Michael <migreen@steptoe.com>; Doh, Tyler <tdoh@steptoe.com>; Kass, Lawrence <lkass@steptoe.com>; Michael Milea <mike.milea@groombridgewu.com>; Joshua Reich <joshua.reich@groombridgewu.com>; [MtrDist] Semaglutide <Semaglutide@Steptoe.com>
Cc: Trials <Trials@USPTO.GOV>
Subject: Re: Conference Call - IPR2023-00724 and IPR2024-00631

We have received the email regarding Monday's call with the Board.

Sincerely,
Megan Raymond

Groombridge, Wu, Baughman & Stone LLP
[801 17th Street, NW, Suite 1050](https://www.groombridge.com)
[Washington, DC 20006](https://www.groombridge.com)
O +1 202-505-5878, M +1 617-388-5878
megan.raymond@groombridgewu.com

From: Molenda, John <imolenda@steptoe.com>

Sent: Friday, March 8, 2024 10:36:44 AM

To: Underwood, Cathy <Cathy.Underwood@USPTO.GOV>; white-ptab@perkinscoie.com <white-ptab@perkinscoie.com>; greb-ptab@perkinscoie.com <greb-ptab@perkinscoie.com>; prochnow-ptab@perkinscoie.com <prochnow-ptab@perkinscoie.com>; jones-ptab@perkinscoie.com <jones-ptab@perkinscoie.com>; tietz-ptab@perkinscoie.com <tietz-ptab@perkinscoie.com>; lembo-ptab@perkinscoie.com <lembo-ptab@perkinscoie.com>; J. Steven Baughman <steve.baughman@groombridgewu.com>; Megan Raymond <megan.raymond@groombridgewu.com>; Green, Michael <migreen@Steptoe.com>; Doh, Tyler <tdoh@Steptoe.com>; Kass, Lawrence <lkass@Steptoe.com>; Michael Milea <mike.milea@groombridgewu.com>; Joshua Reich <joshua.reich@groombridgewu.com>; [MtrDist] Semaglutide <Semaglutide@Steptoe.com>

Cc: Trials <Trials@USPTO.GOV>

Subject: RE: Conference Call - IPR2023-00724 and IPR2024-00631

Some people who received this message don't often get email from jmolenda@steptoe.com. [Learn why this is important](#)

Dear Cathy,

Counsel for Apotex Inc. have received your email and will plan accordingly.

Best regards,
John Molenda

John Josef Molenda, Ph.D.

Partner

Co-Chair, Healthcare & Life Sciences Practice

Pronouns: *he/him/his*

Steptoe

Steptoe LLP | 1114 Avenue of the Americas | New York, NY 10036

+1 212 378 7540 direct | +1 917 549 2189 mobile | +1 212 506 3950 fax | jmolenda@Steptoe.com |

www.steptoe.com

[John Molenda's biography](#)

From: Underwood, Cathy <Cathy.Underwood@USPTO.GOV>

Sent: Friday, March 8, 2024 10:30 AM

To: white-ptab@perkinscoie.com; greb-ptab@perkinscoie.com; prochnow-ptab@perkinscoie.com; jones-ptab@perkinscoie.com; tietz-ptab@perkinscoie.com; lembo-ptab@perkinscoie.com; steve.baughman@groombridgewu.com; megan.raymond@groombridgewu.com; Molenda, John <jmolenda@Steptoe.com>; Green, Michael <migreen@Steptoe.com>; Doh, Tyler <tdoh@Steptoe.com>; Kass, Lawrence <lkass@Steptoe.com>; mike.milea@groombridgewu.com; joshua.reich@groombridgewu.com

Cc: Trials <Trials@USPTO.GOV>

Subject: [EXTERNAL] Conference Call - IPR2023-00724 and IPR2024-00631

Counsel,

A conference call in the above mentioned cases is scheduled for **Monday, March 11 at 10:30 AM ET.**

The call in number is [REDACTED] and the passcode is [REDACTED].

Joining a conference:

1. You must use a touch-tone phone to participate in an Instant Meeting conference.
2. Dial the appropriate access number.

Participants: Enter your numeric participant passcode followed by a # sign.

If you have any questions, please feel free to contact me.
Please confirm receipt of this email.

Thank you,

Cathy Underwood

Trial Paralegal

Patent Trial and Appeal Board

U.S. Patent & Trademark Office

cathy.underwood@uspto.gov

(DIRECT) 571-272-8358

(MAIN) 571-272-9797

This message is intended only for the use of the addressee and may contain confidential and privileged information. Any review, use, or dissemination by anyone other than the addressee is strictly prohibited. If you received this message in error, please notify us and delete all copies of this message.

This message is intended only for the use of the addressee and may contain confidential and privileged information. Any review, use, or dissemination by anyone other than the addressee is strictly prohibited. If you received this message in error, please notify us and delete all copies of this message.

This message is intended only for the use of the addressee and may contain confidential and privileged information. Any review, use, or dissemination by anyone other than the addressee is strictly prohibited. If you received this message in error, please notify us and delete all copies of this message.

message.

This message is intended only for the use of the addressee and may contain confidential and privileged information. Any review, use, or dissemination by anyone other than the addressee is strictly prohibited. If you received this message in error, please notify us and delete all copies of this message.